{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:26:18Z","timestamp":1775197578581,"version":"3.50.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Congenital cytomegalovirus is the leading cause of nongenetic sensorineural hearing loss. Treatment with (val)ganciclovir improves audiologic outcomes. Neutropenia is a common adverse event, but correlates that predict who will develop neutropenia have not been identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data from 3 National Institutes of Health\u2013funded studies of intravenous ganciclovir or oral valganciclovir were evaluated. Baseline absolute neutrophil count (ANC) was defined as high (ANC &gt;1000 cells\/mm<jats:sup>3<\/jats:sup>) or low (ANC \u22641000 cells\/mm<jats:sup>3<\/jats:sup>), and neutropenia was defined as ANC &lt;800 cells\/mm<jats:sup>3<\/jats:sup>. Mean 12-hour area under the curve (AUC<jats:sub>12<\/jats:sub>) ganciclovir values were analyzed as a function of degree of neutropenia using analysis of variance. AUC<jats:sub>12<\/jats:sub> values \u226540 mgxhr\/L were defined as high drug exposure and &lt;40 mgxhr\/L as low drug exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 134 subjects who had AUC<jats:sub>12<\/jats:sub> values obtained during the first week of treatment, 61 (46%) developed neutropenia &lt;800 cells\/mm<jats:sup>3<\/jats:sup>. Infants with high drug exposure developed neutropenia more rapidly than subjects with low drug exposure (median of 28 vs. 216 days; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.008). Although not significant, infants with a baseline ANC \u22641000 cells\/mm<jats:sup>3<\/jats:sup> were observed to develop neutropenia more rapidly compared with those with a high baseline ANC (estimated median of 69 vs. 216 days; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.22) and in greater proportions, although not statistically significant [55.6% vs. 39.3%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.21; odds ratio, 1.9 (95% CI, 0.71\u20135.20)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>High AUC<jats:sub>12<\/jats:sub> correlated with the development of neutropenia in infants treated for symptomatic congenital cytomegalovirus disease. Low baseline ANC also may contribute to the development of neutropenia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004788","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T17:01:37Z","timestamp":1741798897000},"page":"759-763","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Examining Neutropenia During Treatment of Cytomegalovirus Disease in Neonates"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-9662","authenticated-orcid":false,"given":"Javier K.","family":"Nishikawa","sequence":"first","affiliation":[{"name":"Heersink School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Aban","sequence":"additional","affiliation":[{"name":"School of Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Pharmacology and Toxicology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo J.","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Divisions of Neonatology and Pediatric Infectious Diseases, Department of Pediatrics, Nationwide Children\u2019s Hospital, The Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital, Center for Perinatal Research, The Ohio Perinatal Research Network, The Ohio State University College of Medicine, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Kimberlin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus.","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/187152611797636677","article-title":"Overview of congenital infections: the prominence of cytomegalovirus.","volume":"11","author":"Cantey","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-3476(97)70248-8","article-title":"Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection.","volume":"130","author":"Fowler","year":"1997","journal-title":"J Pediatr"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"e20162610","DOI":"10.1542\/peds.2016-2610","article-title":"Hearing loss in children with asymptomatic congenital cytomegalovirus infection.","volume":"139","author":"Lanzieri","year":"2017","journal-title":"Pediatrics"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0194599818758247","article-title":"Hearing trajectory in children with congenital cytomegalovirus infection.","volume":"158","author":"Lanzieri","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease.","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jac\/dkv342","article-title":"Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?","volume":"71","author":"Billat","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.phrs.2016.07.012","article-title":"Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients.","volume":"111","author":"Billat","year":"2016","journal-title":"Pharmacol Res"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/17512433.2023.2181161","article-title":"Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring.","volume":"16","author":"Li","year":"2023","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T20:00:14Z","timestamp":1753300814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004788","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}